Autopsy report · NCT00727194
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 9 months before it stopped.
- 14 participants enrolled.
- Results were posted on the registry 5 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Myasthenia Gravis
- Interventions
- eculizumab; Placebo
- Participants
- 14
- Sites
- 25
- Countries
- Canada, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.